insulin like growth factor binding protein 4Genealiases: BP-4 · HT29-IGFBP · IBP4 · IGFBP-4
Q-omics provides the consensus-scored IGFBP4 profile across patient tissues and cancer cell-line models. IGFBP4 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, IGFBP4 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, IGFBP4 protein abundance shows 21,121 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight BRCA, and KIRC as cancer lineages where IGFBP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IGFBP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IGFBP4 survival associations across molecular data types. IGFBP4 RNA expression shows survival associations in the most cancer types (24), followed by mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IGFBP4 RNA expression–survival associations across cancer types. High IGFBP4 expression shows unfavorable associations in UVM and LGG, but favorable associations in BRCA, UCEC, LIHC and KIRP. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for IGFBP4 RNA expression.
This table summarizes IGFBP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for IGFBP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IGFBP4 shows lower tumor expression in KICH, BLCA, UCEC, LIHC and BRCA and higher tumor expression in KIRC. The KIRC box plot shows higher IGFBP4 RNA expression in tumor versus normal tissue (log2 FC = +1.052, t-test p < 0.001).
This table shows molecular features associated with IGFBP4 in patient tissues and cancer cell lines. In patient samples, IGFBP4 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, IGFBP4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and KIDNEY.
